| Literature DB >> 26965375 |
Dessie Salilew-Wondim1, Sally Ibrahim1, Samuel Gebremedhn1, Dawit Tesfaye2, Maike Heppelmann3, Heinrich Bollwein4, Christiane Pfarrer5, Ernst Tholen1, Christiane Neuhoff1, Karl Schellander1, Michael Hoelker1.
Abstract
BACKGROUND: Clinical and subclinical endometritis are known to affect the fertility of dairy cows by inducing uterine inflammation. We hypothesized that clinical or subclinical endometritis could affect the fertility of cows by disturbing the molecular milieu of the uterine environment. Here we aimed to investigate the endometrial molecular signatures and pathways affected by clinical and subclinical endometritis. For this, Holstein Frisian cows at 42-60 days postpartum were classified as healthy (HE), subclinical endometritis (SE) or clinical endometritis (CE) based on veterinary clinical examination of the animals and histological evaluation the corresponding endometrial biopsies. Endometrial transcriptome and miRNome profile changes and associated molecular pathways induced by subclinical or clinical endometritis were then investigated using GeneChip® Bovine Genome Array and Exiqon microRNA PCR Human Panel arrays, respectively. The results were further validated in vitro using endometrial stromal and epithelial cells challenged with subclinical and clinical doses of lipopolysaccharide (LPS). RESULT: Transcriptome profile analysis revealed altered expression level of 203 genes in CE compared to HE animals. Of these, 92 genes including PTHLH, INHBA, DAPL1 and SERPINA1 were significantly upregulated, whereas the expression level of 111 genes including MAOB, CXCR4, HSD11B and, BOLA, were significantly downregulated in CE compared to the HE animal group. However, in SE group, the expression patterns of only 28 genes were found to be significantly altered, of which 26 genes including PTHLH, INHBA, DAPL1, MAOB, CXCR4 and TGIF1 were common to the CE group. Gene annotation analysis indicated the immune system processes; G-protein coupled receptor signaling pathway and chemotaxis to be among the affected functions in endometritis animal groups. In addition, miRNA expression analysis indicated the dysregulation of 35 miRNAs including miR-608, miR-526b* and miR-1265 in CE animals and 102 miRNAs including let-7 family (let-7a, let-7c, let-7d, let-7d*, let-7e, let-7f, let-7i) in SE animals. Interestingly, 14 miRNAs including let-7e, miR-92b, miR-337-3p, let-7f and miR-145 were affected in both SE and CE animal groups. Further in vitro analysis of selected differentially expressed genes and miRNAs in endometrial stroma and epithelial cells challenged with SE and CE doses of LPS showed similar results to that of the array data generated using samples collected from SE and CE animals.Entities:
Keywords: Bovine; Endometritis; Inflammation; Transcriptome; miRNome
Mesh:
Substances:
Year: 2016 PMID: 26965375 PMCID: PMC4785637 DOI: 10.1186/s12864-016-2513-9
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Fig. 1Dysregulated genes in CE compared to HE animals. a The expression patterns and the hierarchical clustering of 203 genes within and between the biological samples of CE and HE animal groups. The red and green colors indicate the up and downregulated gene expression patterns, respectively. b The fold change and p value of 111 downregulated (green dots) and 92 upregulated genes (red dots) in CE compared to HE animals. The names of some genes are indicated and some others are omitted to enhance visibility. Log2FC on the X axis indicates the fold change difference in log 2 scale. Positive log2FC values represent the upregulation of genes, while negative log2FC values indicate downregulation of genes in CE compared to the HE animal group. The Y axis indicates the p value (bold faced) and FDR (italics in bracket)
Fig. 2The list of differentially expressed genes between SE and HE animal groups. a The expression patterns and the hierarchical clustering of 28 genes within and between the biological samples. The red and green colors indicate up and downregulated gene expression patterns, respectively. b The fold change and p value of downregulated genes (green dots) and the upregulated genes (red dots) in SE compared to HE. The names of some genes are indicated and some others are omitted to enhance visibility. The Affymetrix ID is provided for the transcripts which have no official gene symbol. Log2FC on the X axis indicates the fold change difference in log2 scale. Positive log2FC values represent the upregulation while negative log2FC values indicate downregulation of genes in SE animals compared to the HE group. The Y axis indicates the p value (bold faced) and the FDR (italics in bracket)
Fig. 3Significantly dysregulated genes both in SE and CE animals compared to HE group. a The heatmap illustrating the expression patterns of 26 commonly dysregulated genes in SE and CE animals. The red and green colors in the heatmap indicate high and low expression level of genes, respectively. b The scatter plot showing the relative expression patterns of 8472 genes in SE and CE compared to the HE animal group. The relative expression of SE compared to the HE group (Log2 fold change) is indicated in the X axis while the relative expression of CE animals compared to the HE group (log2 fold change) is plotted in the Y axis. Negative values in the X and Y axis indicated the downregulation of genes while positive values indicated upregulated genes
Functional annotations enriched by the differentially expressed genes
| Functional annotations |
| List of genes |
|---|---|---|
| Response to stimulus | <0.0001 | ↑WNT6, ↓VNN1, ↓TSC22D3, ↓TRIB1, ↑TNC, ↓TLE1, ↓TIMP2, ↑TGIF1, ↑TGFB1I1, ↑STEAP2, ↑SRA1, ↓SOD2, ↑SNAI2, ↑PTHLH, ↓PTGDS, ↓PPP1R1B, ↑POSTN, ↓NKIRAS1, ↓NFIB, ↓NBL1,↑MLLT11, ↓KLF6, ↓KLF4, ↑KCNE1, ↓JUN, ↑INHBA, ↓IGF2, ↓GPR77, ↓F5, ↓EGR1, ↓EFNA1, ↑DNAJC10, ↓CXCR4, ↓CD68, ↑AXIN2, ↓ANGPT4, ↓ALPL, ↓ALDH1A3, ↑AGTR1, ↓AGT, ↑ACTG2 |
| Immune system process | 0.0467 | ↓VNN1, ↓TSC22D3, ↓SOD2, ↓S100B, ↓NBL1, ↓MLF1, ↓KLF4, ↓JUN, ↑INHBA, ↓IGF2, ↓GPR77, ↓EGR1, ↓CXCR4, ↓CFD, ↓APOD |
| Cell adhesion | 0.0009 | ↓VNN1, ↓TGM2, SNAI2, ↑POSTN, KLF4, ↓F5, ↓EMID2, ↓EFNA1, ↑COL1A1, ↓COL13A1, ↓B4GALNT2, ↓APOD, ↓AGT |
| Response to endogenous stimulus | 0.0115 | ↑TGFB1I1, ↑STEAP2, ↑SNAI2, ↓PPP1R1B, ↓NR4A2, ↑KCNE1, ↓JUN, ↓IGF2, ↓EGR1, ↑COL1A1 |
| Enzyme linked receptor protein signaling pathway | 0.0035 | ↑TGIF1, TGFB1I1, ↓NBL1, ↓JUN, ↑INHBA, ↓IGF2, ↓EGR1, ↓EFNA1, ↓APOD, ↓AGT |
| Blood vessel development | 0.0015 | SAT1, KLF4, ↓JUN, ↓EGR1, ↓EFNA1, ↓CXCR4, ↑COL1A1, ↓ANGPT4, ↓AGT, ↑ACTG2 |
| Regulation of neurogenesis | 0.0199 | ↓VLDLR, ↓TIMP2, ↑TGIF1, SDC2, ↓NBL1, ↓EFNA1, ↓CXCR4 |
| Regulation of apoptotic signaling pathway | 0.00703 | ↓VNN1, ↓SOD2, ↑SNAI2, ↑MLLT11, ↑MAGED1, ↑INHBA, ↓AGT |
| G-protein coupled receptor signaling pathway | 0.0212 | ↓SCG5, ↓RGS1, ↑PTHLH, ↑GPR133, ↑AXIN2, ↑AGTR1, ↓AGT |
| Chemotaxis | 0.0125 | ↓NFIB, ↓NBL1, ↓MATN2, ↓GPR77, ↓EFNA1, ↓CXCR4, ↑AGTR1 |
Symbols: ↑ and ↓ indicate the up and downregulation of gene expression, respectively
Validation of differentially expressed genes between CE vs. HE or SE vs. HE using qRT-PCR
| Gene symbol | Array result | qRT-PCR result | Groups | ||
|---|---|---|---|---|---|
| Fold change |
| Fold change |
| ||
|
| 6.9 | 0.001 | 1.96 | 0.00016 | CE vs HE |
|
| 19.2 | 0.000003 | 5.29 | 0.0045 | |
|
| 6.3 | 0.0002 | 1.69 | 0.26 | |
|
| 4.2 | 0.0002 | 3.43 | 0.0002 | |
|
| 4.4 | 0.00003 | 2.29 | <0.0001 | |
|
| 4.2 | 0.0003 | 2.03 | 0.12 | |
|
| 21.1 | 0.00006 | 9.93 | 0.0001 | |
|
| -2.3 | 0.0020 | -2.29 | 0.017 | |
|
| -3.1 | 0.0005 | -3.39 | 0.001 | |
|
| -2.5 | 0.0002 | -2.57 | 0.007 | |
|
| -4.1 | 0.00020 | -3.4 | 0.06 | |
|
| -4.9 | 0.00023 | -3.43 | 0.018 | |
|
| -5.8 | 0.00009 | -3.85 | 0.007 | |
|
| 2.36 | 0.0002 | 4.0 | 0.008 | SE vs HE |
|
| 2.62 | 0.00003 | 10.5 | 0.00003 | |
|
| 1.71 | 0.00023 | 2.13 | 0.003 | |
Positive and and negative values indicate up and down regulation genes in SE or CE compared to HE
Fig. 4The protein level of TNF alpha & IL6 and PGE2: PGF2aa ratio in the cell culture supernatant measured using ELISA in endometrial cells challenged with clinical and subclinical doses of LPS. Control epithelial and control stroma cells describe unchallenged epithelial and stroma cells, respectively. Clin LPS epithelial cells and clin LPS stroma cells designate endometrial epithelial cells and stroma cells challenged with CE equivalents of LPS, respectively whereas sub LPS epithelial cells and sub LPS stroma cells describe the endometrial epithelial cells and stroma cells challenged with SE equivalents of LPS, respectively. * P < 0.05, ** P < 0.01, *** P < 0.001
Fig. 5The expression pattern of candidate genes in the endometrial epithelial and stroma cells challenged with CE and SE doses of LPS in vitro for those upregulated both in SE and CE (a), downregulated in SE (b) or upregulated in CE group (c). Control epithelial and control stroma cells describe unchallenged epithelial and stroma cells, respectively. Clin LPS epithelial cells and clin LPS stroma cells designate endometrial epithelial cells and stroma cells challenged with CE equivalents of LPS, respectively whereas sub LPS epithelial cells and sub LPS stroma cells describe the endometrial epithelial cells and stroma cells challenged with SE equivalents of LPS, respectively. * P < 0.05, ** P < 0.01, *** P < 0.001
Fig. 6Venn diagram indicating exclusively and commonly expressed miRNAs in SE; CE and HE animal groups
Fig. 7The heatmap describing the expression patterns and hierarchical clustering of differentially expressed miRNAs between CE and HE animals. The red and green colors indicate high and low expression patterns, respectively. Thee biological replicates were used for each animal group. FC = fold change
Fig. 8The scatter plot showing the expression patterns of 742 miRNAs in SE and CE compared to the HE animal group. The relative expression of SE compared to HE (Log2 fold change) is indicated in the X axis while the relative expression of CE animal groups relative to HE (log2 fold change) is plotted in the Y axis. Negative log2 fold and positive log2 fold change values in the X and Y axis indicated the upregulated and downregulation of miRNAs, respectively. Only the names of some dysregulated miRNAs are indicated to enhance visibility
Fig. 9The heatmap indicating the expression patterns of the dysregulated miRNAs both in SE and CE compared to HE animal group. The red and green colors indicate high and low miRNA expression, respectively. FC = the relative expression in fold changes
Fig. 10The expression patterns of candidate miRNAs in endometrial epithelial and stroma cells challenged with clinical and subclinical doses of LPS in vitro. Control epithelial and control stroma cells describe unchallenged epithelial and stroma cells, respectively. Clin LPS epithelial cells and clin LPS stroma cells designate endometrial epithelial cells and stroma cells challenged with CE equivalents of LPS, respectively whereas sub LPS epithelial cells and sub LPS stroma cells describe the endometrial epithelial cells and stroma cells challenged with SE equivalents of LPS, respectively. * P < 0.05, ** P < 0.01, *** P < 0.001
MiRNAs downregulated (↓) only in SE animals and the expression patterns of their potential target genes
| miRNAs | Potential target genes | The expression levels of target genes (in fold change) in the SE animals |
|---|---|---|
| miR-128↓ |
| 13.32 |
|
| 2.3 | |
|
| 2.2 | |
|
| 2.03 | |
|
| 1.99 | |
|
| 1.89 | |
| miR-1271↓ |
| 2.3 |
|
| 2.2 | |
|
| 1.85 | |
|
| -2.3 | |
| miR-1266↑ |
| -5 |
|
| -2.6 | |
|
| -1.4 | |
|
| -2.6 | |
|
| -3 | |
| miR-1183↑ |
| -1.6 |
|
| -2.3 | |
|
| -2.6 | |
|
| -5 | |
| miR-181a↓ |
| 13.32 |
|
| 2.6 | |
|
| 2.5 | |
|
| 2.3 | |
|
| 2.2 | |
|
| 2.03 | |
|
| 1.89 | |
| let-7i↓ |
| 3.9 |
|
| 2.5 | |
|
| 2.5 | |
|
| 2.3 | |
|
| 2.2 | |
| let-7c↓ |
| 1.99 |
| let-7a↓ |
| 3.9 |
Positive and negative values indicate up or down regulation of genes, respectively in SE compared to HE
Down (↓) or upregulated (↑) miRNAs only in CE animals and the expression patterns of their target genes
| miRNAs | Potential target genes | The expression levels (in fold change) of target genes in the CE animals |
|---|---|---|
| miR-592↓ |
| 21.3 |
|
| 3.0 | |
|
| 7.0 | |
|
| 2.8 | |
|
| 3.8 | |
|
| 2.3 | |
|
| 2.4 | |
|
| 2.3 | |
|
| 19.6 | |
| miR-608↑ |
| -2.6 |
|
| -2.6 | |
| miR-498↓ |
| 19.3 |
|
| 21.3 | |
|
| 3.4 | |
|
| 7.0 | |
|
| 2.8 | |
|
| 3.8 | |
|
| 2.5 | |
|
| 2.4 | |
|
| 19.6 | |
|
| 2.08 | |
| miR-449b↓ |
| 2.8 |
|
| 2.0 | |
|
| 2.3 | |
| miR-421↓ |
| 2.5 |
| miR-30c↓ |
| 3.0 |
| miR-222↓ |
| 21.3 |
|
| 2.4 | |
|
| 2.0 | |
|
| 2.3 | |
| miR-21↓ |
| 3.4 |
|
| 7.0 | |
|
|
| |
|
| 15.0 | |
|
| 2.0 |
Positive and negative values indicate up and down regulation of genes, respectively in CE compared to HE animals
MiRNAs downregulated (↓) both in CE and SE animals and the expression patterns of their potential target genes
| miRNAs | Target genes | The expression levels of target genes (in fold change) in the CE animals | The expression levels of target genes (in fold change) in the SE animals |
|---|---|---|---|
| miR-196b↓ |
| 2.6 | 2.3 |
| miR-151-5p↓ |
| 2.7 | 2.7 |
|
| 3.8 | 2.3 | |
|
| 2.4 | 1.91 | |
|
| 2.5 | 2.2 | |
|
| 2.3 | 1.8 | |
| miR-1204↓ |
| 2.7 | 2.9 |
|
| 2.51 | 2.7 | |
|
| 3.8 | 2.3 | |
| miR-1203↓ |
| 3.8 | 2.3 |
| let-7f↓ |
| 2.5 | 2.2 |
|
| 2.4 | 2.0 | |
|
| 21.3 | 13.3 | |
|
| 3.6 | 3.9 | |
|
| 4.0 | 2.5 | |
|
| 2.8 | 2.5 | |
|
| 3.8 | 2.3 | |
|
| 2.5 | 2.2 | |
|
| 2.4 | 1.99 | |
|
| 2.0 | 1.89 | |
| let-7e↓ |
| 3.6 | 3.9 |
|
| 2.7 | 2.9 | |
|
| 4.04 | 2.5 | |
|
| 2.8 | 2.5 | |
|
| 3.8 | 2.3 | |
|
| 2.5 | 2.2 | |
|
| 2.4 | 1.99 | |
|
| 2.0 | 1.89 |
Fig. 11Histological sections of endometrial samples of which the corresponding endometrial biopsies which were used for global mRNA and miRNA expression analysis from cows classified as suffering from clinical endometritis (a), subclinical endometritis (b) and healthy animals (c)
Classification of experimental animals as HE, SE or CE based on clinical examination of the animals and histological evaluation of the corresponding endometrial biopsies
| Animal Nr. | Rectal examination | Vaginoscopic examination | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Size (G I-III) | Symmetry (L vs. R) | Contractility (I-III) | Uterine charge (yes/no) | Mucosal color | Wetness (I-V) | Cervix opening (mm) | Discharge (yes/no) | Clinical examination | Histological classification | Overall classification | |
| 245 | III | L > R | I | no | pinkish | II | 3 | no | healthy | in apparent | HE |
| 534 | II | L = R | I | no | pinkish | III | 0 | no | healthy | in apparent | HE |
| 549 | IV | L = R | I-II | no | hyperaemic | IV | 6 | no | healthy | in apparent | HE |
| 665 | II | L < < R | II | no | pale | III | 6 | no | healthy | in apparent | HE |
| 328 | III | L > R | I | no | pinkish | III | 6 | no | healthy | in apparent | HE |
| 613 | II | L = R | II | no | pinkish | III | 3 | no | healthy | in apparent | HE |
| 627 | II | L = R | I | no | pinkish | III | 0 | no | healthy | chronic inflammation | SE |
| 602 | II | L > R | I I | ? | pinkish | II | 3 | no | healthy | in apparent | HE |
| 603 | II | L = R | I | no | pinkish | II | 0 | no | healthy | acute inflammation | SE |
| 550 | III | L < R | II | yes | pinkish | III | 3 | yes | sick | chronic inflammation | CE |
| 369 | II-III | L > R | I-II | yes | pinkish | II | 6 | no | healthy | chronic inflammation | SE |
| 444 | II-III | L > R | K II | no | pinkish | III | 0 | no | healthy | in apparent | HE |
| 459 | II | L = R | I-II | no | pinkish | II | 0 | no | healthy | in apparent | HE |
| 506 | III | L < < R | ? | no | pinkish | III | 3 | no | healthy | in apparent | HE |
| 432 | III | L > R | II-III | no | pinkish | II | 3 | no | healthy | in apparent | HE |
| 470 | II | L = R | I | no | pinkish | III | 3 | no | healthy | in apparent | HE |
| 445 | III | L < R | II | no | pinkish | III | 6 | no | healthy | in apparent | HE |
| 443 | ? | L < R | I-II | no | pinkish | II | 3 | no | healthy | ? | ? |
| 347 | II-III | L = R | II | no | pinkish | III | 6 | no | healthy | in apparent | HE |
| 329 | IV | L < R | I-II | yes | pinkish | III | 3 | yes | sick | chronic inflammation | CE |
| 755 | I-II | L = R | II | no | hyperaemic | II | 3 | yes | sick | chronic inflammation | CE |
| 702 | I | L = R | II | no | pinkish | II | 0 | no | healthy | in apparent | HE |
| 639 | I | L = R | I-II | no | pinkish | III | 0 | no | healthy | inflammation | SE |
| 618 | I | L > R | II | no | pinkish | II | 0 | no | healthy | inflammation | SE |
| 749 | I-II | L = R | II | no | hyperaemic | III | 4.5 | yes | sick | HE | |
| 721 | I-II | L = R | II | yes | hyperaemic | IV | 9 | no | healthy | inflammation | SE |
| 450 | I-II | L = R | II-III | no | pinkish | II | 0 | no | healthy | in apparent | HE |
| 469 | I | L = R | III | no | pinkish | III-IV | 7.5 | no | healthy | in apparent | HE |
| 723 | I-II | L = R | II-III | no | pinkish | III-IV | 6 | no | healthy | in apparent | HE |
| 737 | I | L = R | I-II | yes | pinkish | IV | 9 | yes | sick | in apparent | HE |
| 642 | II | L = R | II | no | pinkish | II-III | 6 | yes | sick | acute inflammation | CE |
| 665 | III | L > R | II | no | pinkish | III | 3 | no | healthy | in apparent | HE |
| 615 | II-III | L = R | I-II | no | pinkish | III | 3 | no | healthy | in apparent | HE |
| 764 | I | L = R | I-II | no | pinkish | II | 3 | no | healthy | in apparent | HE |
| 725 | I-II | L = R | II | no | pinkish/hyperaemic | IV | 7.5 | no | healthy | ? | ? |
| 740 | II | L > R | II | no | blassrosa | II | 6 | no | healthy | ? | ? |
| 606 | I-II | L = R | II | no | pinkish | III | 7.5 | yes | sick | ? | ? |
| 522 | III | L < < R | II | no | pinkish | II | 3 | no | healthy | in apparent | HE |
| 727 | I-II | ? | I-II | no | pinkish | II | 0 | no | healthy | in apparent | HE |
| 729 | I-II | L = R | I-II | no | pinkish | II | 0 | no | healthy | in apparent | HE |
| 728 | II | L = R | I-II | no | pinkish | II | 0 | no | healthy | ? | ? |
| 753 | II | L = R | II-III | no | pinkish | III-IV | 3 | no | healthy | in apparent | HE |
| 767 | II | L < R | I-II | no | pale | I | 0 | no | healthy | ? | ? |
| 736 | I | L = R | II | no | pinkish | II | 3 | yes | sick | ? | ? |
| 696 | II-III | l < R | I-II | yes | hyperaemic | IV | 9 | yes | sick | acute inflammation | CE |
L > R left horn larger than right uterine horn, L < R right horn larger than left uterine horn
Genes and corresponding primers used for validation of the gene expression data using qRT-PCR
| Accession No. | Gene symbol | Gene title | Primer 5‘–3‘ | Bp |
|---|---|---|---|---|
| NM_001077009 |
| Bos taurus purinergic receptor P2Y, G-protein coupled, 14 | F TATGCCAGCCATTTAGAGAGG | 137 |
| R GGAGGTGGGAATTCACAGAG | ||||
| NM_174363.2 |
| Bos taurus inhibin, beta A | F GCAAGGTCAACATCTGCTGTA | |
| R TACAACATGGACATGGGTCTC | ||||
| NM_177944 |
| Bos taurus monoamine oxidase B | F CTATGGCTTTGTGCTTGTCCT | 253 |
| R TCCTGAGAGATGGGATAAAGC | ||||
| NM_001024563.1 |
| Bos taurus potassium voltage-gated channel, Shab-related subfamily, member 2 | F CTCTTTACTTTCTCCGCCAGA | 282 |
| R CATCTTGCACCCTTCTTGACT | ||||
| NM_001083770.1 |
| Bos taurus chromosome 16 open reading frame, human C1orf95 | F GATAGACAGATTCCTGCCTGGT | 268 |
| R TGTTGAGTGTAATGGGGAAGG | ||||
| NM_001077858.2 |
| Bos taurus CTP synthase | F AGGAAGAGGGAAACCAGAGAC | 277 |
| R CCCTTGAGCAAAGCTGTCTAC | ||||
| NM_174753.1 |
| Bos taurus parathyroid hormone-like hormone | F AGCAGAGACCTTCAGAAGACG | 267 |
| R GAAATTCAGCAGCACCAAGA | ||||
| NM_001075835.1 |
| Bos taurus NFKB inhibitor interacting Ras-like 1 | F GACCTTTCGGAACAGAGACAG | 265 |
| R CACGGGTACCTAGAGGCAGT | ||||
| NM_001101105.2 |
| Bos taurus tribbles homolog 1 (Drosophila) | F CGTGTATACCTCACGCACTGT | 287 |
| R CAGCAAACCCAGAGTCCTTAG | ||||
| AF399642.1 |
| Bos taurus CXC chemokine receptor 4, complete cds | F CCACTCCAAAGGCTATCAGAA | 287 |
| R CTCTGCTCACAGAGGTGAGTG | ||||
| NM_173879.2 |
| Bos taurus coagulation factor V (proaccelerin, labile factor) | F GAACGGACTGGAAACCTTACA | 252 |
| R GCCCACTCTAAGTGGTTTGAT | ||||
| NM_174791.4 |
| Bos taurus prostaglandin D2 synthase 21 kDa (brain) | F AGGAAAGACCAGTGTGAGACG | 285 |
| R GAACACAATGCCTTCCTCTGT | ||||
| XM_592894.6 |
| PREDICTED: Bos taurus chordin-like 1 | F CCAGGTGTTCTCTGAAAGCTC | 319 |
| R GGTACTTATGGGCTTTGCTTG |
BP the lengths of the DNA sequence (in base pair)